COMPASS Pathways plc (NASDAQ:CMPS) Receives $33.60 Consensus PT from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $33.60.

Several equities research analysts have recently issued reports on CMPS shares. Royal Bank of Canada restated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Maxim Group decreased their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, HC Wainwright dropped their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, November 1st.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently modified their holdings of CMPS. China Universal Asset Management Co. Ltd. acquired a new stake in COMPASS Pathways in the 4th quarter valued at $41,000. Flagship Harbor Advisors LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $43,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. lifted its position in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Essential Planning LLC. purchased a new position in COMPASS Pathways in the 4th quarter worth approximately $70,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Up 1.4 %

Shares of NASDAQ CMPS opened at $4.47 on Friday. The firm’s 50 day moving average price is $4.10 and its 200 day moving average price is $5.55. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a market cap of $305.84 million, a P/E ratio of -2.03 and a beta of 2.28. COMPASS Pathways has a 1 year low of $3.16 and a 1 year high of $12.75.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.